Madrigal Rezdiffra Sales More Than Double in First Quarter
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) reported first-quarter Rezdiffra sales of $311.3 million, more than doubling from a year earlier as physician adoption accelerated for the company’s liver …
Madrigal Rezdiffra Sales More Than Double in First Quarter Read More